Trice Medical

Executive Summary

Trice Medical is a privately held medical device company founded in 2010 and headquartered in Malvern, Pennsylvania. The company specializes in minimally invasive solutions for soft tissue treatment and surgical visualization, with two core platforms: the Tenex ultrasonic system for percutaneous tissue removal (used in tendinopathy and ligament release) and the mi-eye 3 high-resolution needlescope for arthroscopy. These products address significant unmet needs in orthopedics and sports medicine by enabling less invasive procedures that reduce recovery times and improve patient outcomes. Trice targets a growing market driven by an aging population and increasing demand for outpatient surgeries, positioning itself against larger competitors like Arthrex and Smith & Nephew by focusing on innovation and ease of use. Despite limited publicly available financial data, Trice has established a niche in the minimally invasive surgery space. Its technologies have received positive clinical feedback, and the company continues to expand its product portfolio and geographic reach. Key growth drivers include potential FDA clearances for product enhancements, expansion into new clinical indications, and strategic partnerships with healthcare systems. However, as a private company, visibility into revenue and funding rounds is limited, which moderates near-term conviction. The company's success hinges on its ability to scale commercial adoption and differentiate its offerings in a competitive landscape.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation mi-eye needlescope75% success
• Q4 2026Expansion of Tenex clinical indications to include chronic tendinopathy in additional anatomical sites60% success
• Q1 2027Strategic partnership or distribution agreement for international market entry (e.g., EU or Asia)50% success